Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits. The lead product candidate, ninerafaxstat, is currently in Phase 2 clinical development in three indications: nHCM, stable angina, and HFpEF. For additional information, please visit www.imbria.com.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $98.2M
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | RA Capital... | racap.com |
| 30.04.2025 | AN Venture... | an.vc |
| - | SV Health ... | svhealthin... |
| 09.05.2025 | Catalio Ca... | cataliocap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.04.2025 | Series B | $57.5M | - |
| 03.07.2020 | - | $40.7M | - |
Mentions in press and media 15
| Date | Title | Description |
| 19.11.2025 | Imbria Pharmaceuticals Extends Series B | Imbria Pharmaceuticals, Inc., a Boston, MA-based clinical-stage company developing cardiovascular disease therapeutics, received an investment from AXA IM Alts in an upsized Series B financing. With this investment, AXA IM Alts joined the s... |
| 17.11.2025 | Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases | New investor AXA IM Alts joins upsized Series B round to support clinical advancement and expand global health impact of ninerafaxstat, a novel cardiovascular therapeutic Dr. Zina Affas Besse (AXA IM Alts) and Mr. Ken Horne (AN Ventures) ap... |
| 15.04.2025 | Imbria Pharmaceuticals: $57.5 Million (Series B) Raised To Develop Novel Therapies For Cardiometabolic Diseases | Imbria Pharmaceuticals – a clinical-stage biotechnology company developing novel therapies for cardiometabolic diseases with high unmet need – announced the closing of a $57.5 million Series B funding with a top-tier syndicate of life scien... |
| 11.04.2025 | Imbria Pharmaceuticals: A New Dawn in Cardiometabolic Treatment | Imbria Pharmaceuticals is on the rise. The Boston-based biotech company recently secured $57.5 million in a Series B financing round. This funding is a lifeline, aimed at advancing their promising drug, ninerafaxstat, for treating non-obstr... |
| 11.04.2025 | Imbria Pharmaceuticals Raises $57.5M in Series B Financing | Imbria Pharmaceuticals, Inc., a Boston, MA-based clinical stage biotechnology company developing novel therapies for cardiometabolic diseases with high unmet need, closed a $57.5m Series B financing. The round was led by new investor, Deep ... |
| 10.04.2025 | Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO | BOSTON, Mass., April 10, 2025 – Imbria Pharmaceuticals, Inc., a clinical stage biotechnology company developing novel therapies for cardiometabolic diseases with high unmet need, today announced the successful closing of a $57.5 million Ser... |
| 10.04.2025 | Imbria Pharmaceuticals Pulls In $57.5M Series B | BOSTON, MA, Imbria Pharmaceuticals today announced the successful closing of a $57.5 million Series B financing round. >> Click here for more funding data on Imbria Pharmaceuticals >> To export Imbria Pharmaceuticals funding da... |
| 10.04.2025 | Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO | – Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA Capital Management and SV Health Investors – – Proceeds to support advancement of ninera... |
| 08.04.2024 | Positive Results for Patients with Non-obstructive Hypertrophic Cardiomyopathy Treated with Ninerafaxstat in the Phase 2 IMPROVE-HCM Trial Presented During a Late-Breaking Clinical Trial Session at AC... | BOSTON, Mass., April 8, 2024 – Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to improve patient symptoms and functional capacity by enhancing cellular energetics, today announced... |
| 07.11.2023 | Imbria Reports Positive Topline Results for Investigational New Drug Ninerafaxstat in Patients with Non-obstructive Hypertrophic Cardiomyopathy | – The IMPROVE-HCM Phase 2 clinical trial met the primary endpoint of safety and tolerability; 12-weeks treatment with ninerafaxstat also demonstrated a statistically significant improvement, compared to placebo, in a robust functional cardi... |
Show more